BidaskClub upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a strong sell rating to a sell rating in a research report sent to investors on Thursday.
CLDX has been the subject of a number of other research reports. HC Wainwright restated a buy rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. WBB Securities reiterated a buy rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, December 6th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $7.05.
Shares of Celldex Therapeutics (CLDX) opened at $2.37 on Thursday. The firm has a market capitalization of $322.29, a price-to-earnings ratio of -2.35 and a beta of 2.57. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.94.
TRADEMARK VIOLATION NOTICE: “Celldex Therapeutics (CLDX) Upgraded to Sell at BidaskClub” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3222244/celldex-therapeutics-cldx-upgraded-to-sell-at-bidaskclub.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.